Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-Resistant Ovarian Cancer

This study has been completed.
Massachusetts General Hospital
Dana-Farber Cancer Institute
Information provided by:
Cellectar Biosciences, Inc. Identifier:
First received: June 26, 2006
Last updated: January 8, 2009
Last verified: January 2009
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2008
  Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)